| AD | Alzheimer’s disease |
| Aβ | Amyloid-β peptide |
| Bcl-2 | B-cell lymphoma 2 |
| BDNF | Brain-derived neurotrophic factor |
| cAMP | Cyclic adenosine monophosphate |
| CNS | Central nervous system |
| COPD | Chronic obstructive pulmonary disease |
| CR3 | Control region 3 |
| CREB | cAMP response element binding protein |
| ele | electrostatic interactions |
| Epac1/2 | Exchange factor directly activated by cAMP 1 and 2 |
| ESP | Electrostatic potential |
| FDA | Food and Drug Administration |
| FEP | Free energy perturbation |
| GAFF | General AMBER force field |
| HF | Hartree-Fock |
| IBD | Inflammatory bowel diseases |
| IL-1β | Interleukin 1 beta |
| IL-6 | Interleukin 6 |
| LIE | Linear interaction energy |
| LRA | Linear response approximation |
| LRF | Local reaction field |
| MD | Molecular dynamics |
| PDB | Protein data bank |
| PDE4 | Phosphodiesterase 4 |
| PKA | Protein kinase A |
| RA | Rheumatic arthritis |
| RESP | Restricted electrostatic charge fitting procedure |
| PLIP | Protein ligand interaction profiler |
| RMR6 | Radial-mean-reduced scoring function at a cutoff radius of 6 Å from each atom of the ligand |
| RMSD | Root mean square deviation |
| RMSF | Root mean square fluctuation |
| ROS | Reactive oxygen species |
| SCAAS | Surface constraint all-atom solvent |
| UCR1 | Upstream conserved region 1 |
| UCR2 | Upstream conserved region 2 |
| vdW | van der Waals interactions |